Updated Jul 16, 2026
Espinoza Octavio has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $4.04M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-06 | LGND | LIGAND PHARMACEUTICALS INC | J — Other acquisition / disposition | 17 | $160.71 | $3K |
| 2026-05-28 | LGND | LIGAND PHARMACEUTICALS INC | M — Option exercise | 972 | $52.84 | $51K |
| 2026-05-28 | LGND | LIGAND PHARMACEUTICALS INC | M — Option exercise | 764 | $63.62 | $49K |
| 2026-03-28 | LGND | LIGAND PHARMACEUTICALS INC | A — Grant or award | 4.9K | $0.00 | |
| 2026-03-13 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 3.1K | $225.00 | $688K |
| 2026-03-13 | LGND | LIGAND PHARMACEUTICALS INC | M — Option exercise [10b5-1] | 2.4K | $92.65 | $223K |
| 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 3.4K | $208.80 | $713K |
| 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 2.5K | $207.91 | $511K |
| 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 1.6K | $206.89 | $329K |
| 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 1.5K | $205.79 | $300K |
| 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 743 | $204.74 | $152K |
| 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 668 | $203.63 | $136K |
| 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 697 | $202.79 | $141K |
| 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 950 | $201.73 | $192K |
| 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 698 | $201.09 | $140K |
| 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 53 | $200.08 | $11K |
| 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 699 | $198.71 | $139K |
| 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | M — Option exercise [10b5-1] | 466 | $80.72 | $38K |
| 2026-03-06 | LGND | LIGAND PHARMACEUTICALS INC | M — Option exercise [10b5-1] | 1.6K | $58.49 | $94K |
| 2026-02-18 | LGND | LIGAND PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 1.3K | $183.83 | $233K |
Espinoza Octavio is a corporate insider — currently tracked as Chief Financial Officer of LIGAND PHARMACEUTICALS INC (LGND). InsiderAlpha tracks every SEC Form 4 filing in real time.
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 14 open-market sales ($4.04M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Espinoza Octavio profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.